40, Dalton St

Boston,

MA,

USA,

ZIP: 02115

Phone: +16174554188

2023 welcomed SV95C as the first ever digital endpoint qualified by a regulatory agency, which means that the floodgates have now opened to the potential of digital biomarkers to transform clinical development in neurology.

From the latest validated research on implementing speech, cognition, and motor tracking measures into clinical development, to navigating the regulatory and commercial landscape, the 3rd Digital Biomarkers and Clinical Measures for Neurology Summit is the ultimate platform to take your digital strategy to the next level.

This August, join 80+ senior industry leaders across digital health, medical affairs, clinical development, and regulatory this year from Biogen, DEEP Measures, Janssen, Alexion Pharmaceuticals, Eisai, Pfizer, Novo Nordisk, Novartis, Boehringer Ingelheim, Takeda, MTP, BMS, Alto Neurosciences, Michael J. Fox Foundation, Cerevel Therapeutics, Regeneron and many more...

URLs:
Tickets: https://go.evvnt.com/2431357-2?pid=1052
Brochure: https://go.evvnt.com/2431357-3?pid=1052

Prices:
Conference + 2 Workshops - Solution Providers - On the door: USD 5097.00,
Conference + 1 Workshop - Solution Providers - On the door: USD 4398.00,
Conference only - Solution Providers - On the door: USD 3699.00,
Conference + 2 Workshops - Academics and Start-Ups - On the door: USD 2897.00,
Conference + 1 Workshop - Academics and Start-Ups - On the door: USD 2548.00,
Conference only - Academics and Start-Ups - On the door: USD 2199.00,
Conference + 2 Workshops - Drug Developers - On the door: USD 3497.00,
Conference + 1 Workshop - Drug Developers - On the door: USD 3048.00,
Conference only - Drug Developers - On the door: USD 2599.00

Speakers: Abhishek Pratap, Senior Clinical Program Leader, CNS, Boehringer Ingelheim, Ankita Deshpande, Head of Digital Health and Experience Innovation, Alexion Pharmaceuticals, Bhaskar Dutta, Head of Digital Health and Medical Affairs Technologies, Alexion Pharmaceuticals, Bruce Morimoto, Vice President, Alto Neuroscience, Bryan Cobb, Principal Medical Science Director, Eisai, Carrie Northcott, Head of Digital Sciences, Pfizer, Cyndi Grossman, Head, Real-World Research Networks, Biogen (formerly), Elias Abou Zeid, Associate Director and Principal Data Scientist, Data Artificial Intelligence and Analytics, Novo Nordisk, Gayle Wittenberg, Vice President, Neuroscience, Johnson and Johnson, Gul Erdemli, Global Regulatory Program Director, Novartis, John Wilbanks, Head of Data, Biogen Digital Health, Biogen, Karla Allebrandt, Principal Clinical Biomarker Lead and Director of External Collaborations, Boehringer Ingelheim, Katerina Placek, Senior Manager, Digital Health Sciences, Takeda Pharamceuticals, Mark Gudesblatt, Head of Science Advisory Board, Innovative Precision Health, South Shore Neurologic Associates, NYU Langone, Ram Miller Executive Director, Translational Medicine and Neuromuscular Disease, Novartis, Rauha Tulkki-Wilke, Chief Product Officer, DEEP Measures, Sharon Tamir, Digital Healthcare Innovation, Business and Research Strategy, Mitsubishi Tanabe Pharma, Sonya Dumanis, Executive Vice President, Coalition for Aligning Science, Srikanth Gottipati, Director, Digital Transformation Sciences, Cerevel Therapeutics, Vijaya Kolachalama, Associate Professor of Medicine and Computer Science, Boston University, Viprali Bhatkar, Senior Director, Digital Health, Bristol Myers Squibb, Wolfgang Liedtke, Professor of Neurology, Anesthesiology and Neurobiology, Duke University, Professor of Dentistry, NYU Pain Research Center College of Dentistry, Yuge Xiao, Associate Director, Clinical Research, The Michael J. Fox Foundation, Bola Grace, Honorary Professor, UCL